Trial Profile

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Bendamustine (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms BendAlem

Most Recent Events

06 Mar 2015 According to the ClinicalTrials.gov record, changed from 1 Jun 2013 to 1 Jun 2015.
06 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2013 to 1 Jun 2015.
04 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com